What is the efficacy and safety of synthetic prostacyclin therapies or prostacyclin receptor agonists for managing pulmonary arterial hypertension?

Pulmonary hypertension is defined as elevated mean pulmonary arterial pressure and increased pulmonary resistance. The World Health Organization (WHO) has divided pulmonary hypertension into 5 types on the basis of pathophysiology, clinical presentation, and treatment options.1  One of those types, pulmonary arterial hypertension (PAH), is characterized by narrowing or blockage of pulmonary blood vessels, causing decreased blood flow and elevated blood pressure within the pulmonary arteries. As a result, the heart has to pump harder, and eventually the heart muscle can weaken.2 

Millions of people are affected by PAH annually, and its prevalence has steadily increased over the last several years.3  Several treatment options for PAH are available, with the goals of relieving symptoms, improving exercise capacity, preventing or slowing progression, and improving overall quality of life. People...

You do not currently have access to this content.